Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12743672,bioavailability,"The mean (+/- standard deviation) bioavailability of melagatran was 22.2+/-4.3% and 17.4+/-2.8% after single and repeated dosings, respectively.","Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12743672/),%,22.2,9413,DB04898,Ximelagatran
,12743672,bioavailability,"The mean (+/- standard deviation) bioavailability of melagatran was 22.2+/-4.3% and 17.4+/-2.8% after single and repeated dosings, respectively.","Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12743672/),%,17.4,9414,DB04898,Ximelagatran
,12742279,International Normalized Ratio,"In a fourth group, warfarin (n = 67) was managed and monitored according to normal routines, aiming for an International Normalized Ratio of 2.0 to 3.0.","Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742279/),,2.0 to 3.0,9596,DB04898,Ximelagatran
,12955372,t1/2,"The geometric means of the t1/2 for melagatran were 4.0 h and 4.2 h for the first and last doses, respectively, in patients, and 3.5 h and 3.7 h, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),h,4.0,16525,DB04898,Ximelagatran
,12955372,t1/2,"The geometric means of the t1/2 for melagatran were 4.0 h and 4.2 h for the first and last doses, respectively, in patients, and 3.5 h and 3.7 h, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),h,4.2,16526,DB04898,Ximelagatran
,12955372,t1/2,"The geometric means of the t1/2 for melagatran were 4.0 h and 4.2 h for the first and last doses, respectively, in patients, and 3.5 h and 3.7 h, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),h,3.5,16527,DB04898,Ximelagatran
,12955372,t1/2,"The geometric means of the t1/2 for melagatran were 4.0 h and 4.2 h for the first and last doses, respectively, in patients, and 3.5 h and 3.7 h, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),h,3.7,16528,DB04898,Ximelagatran
,12955372,F,"Geometric means of F of melagatran following oral administration of ximelagatran were 22% and 24% for the first and last doses, respectively, in patients and 21% and 23%, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),%,22,16529,DB04898,Ximelagatran
,12955372,F,"Geometric means of F of melagatran following oral administration of ximelagatran were 22% and 24% for the first and last doses, respectively, in patients and 21% and 23%, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),%,24,16530,DB04898,Ximelagatran
,12955372,F,"Geometric means of F of melagatran following oral administration of ximelagatran were 22% and 24% for the first and last doses, respectively, in patients and 21% and 23%, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),%,21,16531,DB04898,Ximelagatran
,12955372,F,"Geometric means of F of melagatran following oral administration of ximelagatran were 22% and 24% for the first and last doses, respectively, in patients and 21% and 23%, respectively, in controls.",Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955372/),%,23,16532,DB04898,Ximelagatran
,11228340,Oral bioavailability,"Oral bioavailability, measured as melagatran in plasma, is about 20% after oral administration of H 376/95, which is 2.7-5.5 times higher than after oral administration of melagatran.","The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11228340/),%,20,24799,DB04898,Ximelagatran
,11228340,inhibition constant (K(i)) ratio,"Pharmacodynamic properties: H 376/95 is inactive towards human alpha-thrombin compared with melagatran [inhibition constant (K(i)) ratio, 185 times], a potential advantage for patients with silent gastrointestinal bleeding.","The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11228340/),times,185,24800,DB04898,Ximelagatran
,18458048,biliary clearance,Erythromycin increased the area under the plasma concentration-time curve (AUC) of melagatran by 45% and reduced its biliary clearance from 3.0 +/- 1.3 to 1.5 +/- 1.1 ml/min/kg.,Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18458048/),[ml] / [kg·min],3.0,40359,DB04898,Ximelagatran
,18458048,biliary clearance,Erythromycin increased the area under the plasma concentration-time curve (AUC) of melagatran by 45% and reduced its biliary clearance from 3.0 +/- 1.3 to 1.5 +/- 1.1 ml/min/kg.,Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18458048/),[ml] / [kg·min],1.5,40360,DB04898,Ximelagatran
,18458048,f(abs),Intestinal efflux transporters seemed to be of minor importance for the disposition of ximelagatran and its metabolites considering the high estimated f(abs) of ximelagatran (80 +/- 20%) and the negligible amount of the compounds excreted in the perfused intestinal segment.,Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18458048/),%,80,40361,DB04898,Ximelagatran
,12851531,IC(50),"The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively.","Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851531/),[μM] / [l],0.44,99817,DB04898,Ximelagatran
,12851531,IC(50),"The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively.","Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851531/),[iu] / [ml],0.06,99818,DB04898,Ximelagatran
,12739985,bioavailability,"The interindividual variability of melagatran AUC was low (coefficient of variation 19-26%), and the mean bioavailability of melagatran, estimated using a mean value for melagatran clearance obtained from Caucasian subjects in a previous study, was approximately 20% in all groups (range of mean values 19-23%).","No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739985/),%,20,113678,DB04898,Ximelagatran
,15903126,Clearance,"Clearance after oral administration (population mean, 27.3 L/h) was correlated with creatinine clearance (P < 10(-6)), and volume of distribution (population mean, 176 L) was correlated with body weight (P = 2 x 10(-5)).",Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15903126/),[l] / [h],27.3,114293,DB04898,Ximelagatran
,15903126,volume of distribution,"Clearance after oral administration (population mean, 27.3 L/h) was correlated with creatinine clearance (P < 10(-6)), and volume of distribution (population mean, 176 L) was correlated with body weight (P = 2 x 10(-5)).",Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15903126/),l,176,114294,DB04898,Ximelagatran
,15903126,total plasma clearance,"Unexplained interpatient variability values in total plasma clearance and bioavailability were 19% and 21%, respectively.",Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15903126/),%,19,114295,DB04898,Ximelagatran
,15903126,bioavailability,"Unexplained interpatient variability values in total plasma clearance and bioavailability were 19% and 21%, respectively.",Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15903126/),%,21,114296,DB04898,Ximelagatran
,15903126,area under the plasma melagatran concentration versus time curve,"The median area under the plasma melagatran concentration versus time curve across all patients and dose levels was 3.22 h x micromol/L (5th-95th percentiles, 1.35-7.69).",Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15903126/),[h·μM] / [l],3.22,114297,DB04898,Ximelagatran
,12648028,Renal clearance,"Renal clearance of melagatran, was 7.7 L/h and 4.9 L/h in the younger and older subjects, respectively.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),[l] / [h],7.7,123312,DB04898,Ximelagatran
,12648028,Renal clearance,"Renal clearance of melagatran, was 7.7 L/h and 4.9 L/h in the younger and older subjects, respectively.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),[l] / [h],4.9,123313,DB04898,Ximelagatran
,12648028,bioavailability,"The mean bioavailability of melagatran in young and older subjects was approximately 18 and 12% , respectively, following oral administration of ximalagratan, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),%,18,123314,DB04898,Ximelagatran
,12648028,bioavailability,"The mean bioavailability of melagatran in young and older subjects was approximately 18 and 12% , respectively, following oral administration of ximalagratan, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),%,12,123315,DB04898,Ximelagatran
,12648028,bioavailability,"The mean bioavailability of melagatran in young and older subjects was approximately 18 and 12% , respectively, following oral administration of ximalagratan, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),%,38,123316,DB04898,Ximelagatran
,12648028,bioavailability,"The mean bioavailability of melagatran in young and older subjects was approximately 18 and 12% , respectively, following oral administration of ximalagratan, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran.","Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648028/),%,45,123317,DB04898,Ximelagatran
,12846595,CL(R),"In the severe renal impairment and control groups, respectively, the mean CL(R) of melagatran was 12.5 and 81.3 mL/min after subcutaneous administration of melagatran and 14.3 and 107 mL/min after oral administration of ximelagatran.",Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846595/),[ml] / [min],12.5,132359,DB04898,Ximelagatran
,12846595,CL(R),"In the severe renal impairment and control groups, respectively, the mean CL(R) of melagatran was 12.5 and 81.3 mL/min after subcutaneous administration of melagatran and 14.3 and 107 mL/min after oral administration of ximelagatran.",Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846595/),[ml] / [min],81.3,132360,DB04898,Ximelagatran
,12846595,CL(R),"In the severe renal impairment and control groups, respectively, the mean CL(R) of melagatran was 12.5 and 81.3 mL/min after subcutaneous administration of melagatran and 14.3 and 107 mL/min after oral administration of ximelagatran.",Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846595/),[ml] / [min],14.3,132361,DB04898,Ximelagatran
,12846595,CL(R),"In the severe renal impairment and control groups, respectively, the mean CL(R) of melagatran was 12.5 and 81.3 mL/min after subcutaneous administration of melagatran and 14.3 and 107 mL/min after oral administration of ximelagatran.",Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846595/),[ml] / [min],107,132362,DB04898,Ximelagatran
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.376,136505,DB04898,Ximelagatran
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.163,136506,DB04898,Ximelagatran
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.115,136507,DB04898,Ximelagatran
,12846596,elimination half-life (t1/2z),The maximum plasma concentration of melagatran (Cmax) was achieved 2-3 hours after administration; the mean elimination half-life (t1/2z) was 3.6 hours for hepatically impaired volunteers and 3.1 hours for the control volunteers.,"No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846596/),h,3.6,148380,DB04898,Ximelagatran
,12846596,elimination half-life (t1/2z),The maximum plasma concentration of melagatran (Cmax) was achieved 2-3 hours after administration; the mean elimination half-life (t1/2z) was 3.6 hours for hepatically impaired volunteers and 3.1 hours for the control volunteers.,"No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846596/),h,3.1,148381,DB04898,Ximelagatran
,17516699,Bioavailability,Bioavailability of melagatran was 21% after the first oral dose of ximelagatran and was virtually unchanged throughout the study.,"Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516699/),%,21,194292,DB04898,Ximelagatran
,12584156,bioavailability,"The bioavailability of melagatran following oral administration of ximelagatran was 5 to 10% in rats, 10 to 50% in dogs, and about 20% in humans, with low between-subject variation.","Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584156/),%,5 to 10,195648,DB04898,Ximelagatran
,12584156,bioavailability,"The bioavailability of melagatran following oral administration of ximelagatran was 5 to 10% in rats, 10 to 50% in dogs, and about 20% in humans, with low between-subject variation.","Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584156/),%,10 to 50,195649,DB04898,Ximelagatran
,12584156,bioavailability,"The bioavailability of melagatran following oral administration of ximelagatran was 5 to 10% in rats, 10 to 50% in dogs, and about 20% in humans, with low between-subject variation.","Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584156/),%,20,195650,DB04898,Ximelagatran
,12584156,fraction,The fraction of ximelagatran absorbed was at least 40 to 70% in all species.,"Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584156/),%,40,195651,DB04898,Ximelagatran
,15081569,lag phase,"Ximelagatran (30 mg, 3.79 min, 3.52-4.08 at 2 h), r-hirudin (6.23 min, 4.93-7.86 at 2 h), and enoxaparin (4.68 min, 3.30-6.64 at 2 h) also delayed the lag phase before the thrombin generation burst compared to placebo (2.92 min, 2.71-3.25 at 2 h).","The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081569/),min,2.92,206793,DB04898,Ximelagatran
,12818629,bioavailability,"Ximelagatran is therefore much better than melagatran at penetrating the gastrointestinal barrier and, as a consequence, has sufficient bioavailability (20%) for oral administration.",The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818629/),%,20,213333,DB04898,Ximelagatran
,12974871,Oral bioavailability,"Oral bioavailability, measured as the plasma concentration of the active metabolite, seems to be higher for ximelagatran (20%) than for BIBR 1048 (estimated to 5%).",Oral direct thrombin inhibitors in clinical development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),%,20,230458,DB04898,Ximelagatran
,12974871,Oral bioavailability,"Oral bioavailability, measured as the plasma concentration of the active metabolite, seems to be higher for ximelagatran (20%) than for BIBR 1048 (estimated to 5%).",Oral direct thrombin inhibitors in clinical development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),%,5,230459,DB04898,Ximelagatran
,12974871,half-life,"BIBR 953 has a longer half-life (about 12 h) than does melagatran (3-5 h) after oral administration of BIBR 1048 and ximelagatran, respectively.",Oral direct thrombin inhibitors in clinical development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),h,12,230460,DB04898,Ximelagatran
,12974871,half-life,"BIBR 953 has a longer half-life (about 12 h) than does melagatran (3-5 h) after oral administration of BIBR 1048 and ximelagatran, respectively.",Oral direct thrombin inhibitors in clinical development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12974871/),h,3-5,230461,DB04898,Ximelagatran
,12215755,elimination half-life,"As these substances are eliminated via liver or kidneys with an elimination half-life of 0.3-2 hours, parenteral administration should be used for acute therapy and prophylaxis.",[Rationale for an oral thrombin inhibitor from a pharmacological point of view]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12215755/),h,0.3-2,237936,DB04898,Ximelagatran
,12215755,absorption rates,"For long-term prophylaxis, orally absorbable derivatives of these direct thrombin inhibitors are available with absorption rates of 10-30%.",[Rationale for an oral thrombin inhibitor from a pharmacological point of view]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12215755/),%,10-30,237937,DB04898,Ximelagatran
,15025841,area under the plasma concentration-versus-time curve (AUC),"The mean area under the plasma concentration-versus-time curve (AUC) of melagatran was 1.6 micromol.h/L (ratio 1.01 for treatment II/I and 0.97 for treatment III/I), the mean peak concentration (C(max)) was 0.3 micromol/L (ratio 1.04 for treatment II/I and 1.02 for treatment III/I) and the mean half-life (t(1/2)) was 2.8 h for all treatments.","Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025841/),[h·μM] / [l],1.6,241292,DB04898,Ximelagatran
,15025841,peak concentration (C(max)),"The mean area under the plasma concentration-versus-time curve (AUC) of melagatran was 1.6 micromol.h/L (ratio 1.01 for treatment II/I and 0.97 for treatment III/I), the mean peak concentration (C(max)) was 0.3 micromol/L (ratio 1.04 for treatment II/I and 1.02 for treatment III/I) and the mean half-life (t(1/2)) was 2.8 h for all treatments.","Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025841/),[μM] / [l],0.3,241293,DB04898,Ximelagatran
,15025841,half-life (t(1/2)),"The mean area under the plasma concentration-versus-time curve (AUC) of melagatran was 1.6 micromol.h/L (ratio 1.01 for treatment II/I and 0.97 for treatment III/I), the mean peak concentration (C(max)) was 0.3 micromol/L (ratio 1.04 for treatment II/I and 1.02 for treatment III/I) and the mean half-life (t(1/2)) was 2.8 h for all treatments.","Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025841/),h,2.8,241294,DB04898,Ximelagatran
,15025841,time to C(max) (t(max)),"The time to C(max) (t(max)) was 2.2h for the whole tablet and approximately 0.5 h earlier when the tablet was crushed or dissolved (1.7-1.8 h), due to a more rapid absorption.","Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025841/),h,2.2,241295,DB04898,Ximelagatran
,15025841,time to C(max) (t(max)),"The time to C(max) (t(max)) was 2.2h for the whole tablet and approximately 0.5 h earlier when the tablet was crushed or dissolved (1.7-1.8 h), due to a more rapid absorption.","Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025841/),h,0.5,241296,DB04898,Ximelagatran
,15025841,time to C(max) (t(max)),"The time to C(max) (t(max)) was 2.2h for the whole tablet and approximately 0.5 h earlier when the tablet was crushed or dissolved (1.7-1.8 h), due to a more rapid absorption.","Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15025841/),h,1.7-1.8,241297,DB04898,Ximelagatran
,16123911,bioavailability,"The bioavailability of melagatran, the active form of ximelagatran, after oral administration of ximelagatran is approximately 20% with low inter- and intra-individual variability.",Pharmacokinetics and pharmacodynamics of ximelagatran. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123911/),%,20,245703,DB04898,Ximelagatran
,16123911,half-life,"Peak plasma melagatran concentrations are reached approximately 2 hours after oral dosing of ximelagatran to healthy volunteers, and melagatran is eliminated with a half-life of approximately 3 hours with clearance predominantly by renal excretion.",Pharmacokinetics and pharmacodynamics of ximelagatran. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123911/),h,3,245704,DB04898,Ximelagatran
,12844328,population clearance,"The median population clearance (creatinine clearance 70 mL/min) was 5.3 and 22.9 L/h for the subcutaneous and oral formulations, respectively.",Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844328/),[l] / [h],5.3,264579,DB04898,Ximelagatran
,12844328,population clearance,"The median population clearance (creatinine clearance 70 mL/min) was 5.3 and 22.9 L/h for the subcutaneous and oral formulations, respectively.",Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844328/),[l] / [h],22.9,264580,DB04898,Ximelagatran
,12844328,bioavailability,The bioavailability of melagatran after oral ximelagatran relative to subcutaneous melagatran was 23%.,Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844328/),%,23,264581,DB04898,Ximelagatran
